Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) stock jumped 6.68% on Monday to $0.43 against a previous-day closing price of $0.41. With 2.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 66480.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4343 whereas the lowest price it dropped to was $0.4050. The 52-week range on GLMD shows that it touched its highest point at $14.18 and its lowest point at $0.35 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 0.97.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GLMD was up-trending over the past week, with a rise of 23.03%, but this was up by 4.05% over a month. Three-month performance dropped to -48.66% while six-month performance fell -91.66%. The stock lost -91.46% in the past year, while it has lost -94.21% so far this year. EPS is expected to grow by 20.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 6.23%.
Float and Shares Shorts:
At present, 3.81 million GLMD shares are outstanding with a float of 3.55 million shares on hand for trading. On Oct 30, 2023, short shares totaled 10970.0, which was 0.27% higher than short shares on Sep 28, 2023. In addition to Mr. Allen Baharaff as the firm’s Co-Founder, President, CEO & Chairman, Mr. Doron Cohen serves as its Chief Financial Officer.
Through their ownership of 15.26% of GLMD’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 16.80% of GLMD, in contrast to 0.58% held by mutual funds. As the largest shareholder in GLMD with 6.56% of the stake, Walleye Capital LLC holds 249,763 shares worth 249,763. A second-largest stockholder of GLMD, Heights Capital Management, Inc., holds 249,384 shares, controlling over 6.55% of the firm’s shares. Two Sigma Advisers LP is the third largest shareholder in GLMD, holding 50,633 shares or 1.33% stake. With a 0.54% stake in GLMD, the Delaware Healthcare Fund is the largest stakeholder. A total of 20,400 shares are owned by the mutual fund manager. The Fidelity Nasdaq Composite Index F, which owns about 0.05% of GLMD stock, is the second-largest Mutual Fund holder. It holds 1,813 shares valued at 689.0. Vifag 2002, SICAV holds 0.00% of the stake in GLMD, owning 0 shares worth 0.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GLMD since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GLMD analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, GLMD could surge 830.23% to reach the target high and rise by 830.23% to reach the target low. Reaching the average price target will result in a growth of 830.23% from current levels.